Drugs / GPC3-CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05344664 | Apr 2022 → Oct 2024 | — | Peking University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | Eutilex | Results 경쟁자 털어낸 유틸렉스…EU307 성공이끌 핵심열쇠 두 가지 eutilex.com ↗
미국 메카인 베일러 의대에서 개발된 GPC3-CAR-T(IL15.CAR) 치료제는 GPC3 양성 간세포암 환자에서 33%의 반응률을 보였고 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | Eutilex | 경쟁자 털어낸 유틸렉스…EU307 성공이끌 핵심열쇠 두 가지 eutilex.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPC3-CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05344664 ↗ |
| Modality | Cell therapy | “GPC3 CAR-T cell immunotherapy” NCT05344664 ↗ |
| Target | GPC3 | “GPC3 CAR-T cells” NCT05344664 ↗ |